Jounce Therapeutics, Inc. Quarterly Operating Income (Loss) in USD from Q1 2016 to Q4 2022

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Jounce Therapeutics, Inc. quarterly/annual Operating Income (Loss) history and growth rate from Q1 2016 to Q4 2022.
  • Jounce Therapeutics, Inc. Operating Income (Loss) for the quarter ending December 31, 2022 was $50.3M.
  • Jounce Therapeutics, Inc. Operating Income (Loss) for the twelve months ending December 31, 2022 was -$52.2M, a 42.6% increase year-over-year.
  • Jounce Therapeutics, Inc. annual Operating Income (Loss) for 2022 was -$52.2M, a 42.6% increase from 2021.
  • Jounce Therapeutics, Inc. annual Operating Income (Loss) for 2021 was -$91.1M, a 102% decline from 2020.
  • Jounce Therapeutics, Inc. annual Operating Income (Loss) for 2020 was -$45.1M, a 185% decline from 2019.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q4 2022 -$52.2M $50.3M +$80.6M Oct 1, 2022 Dec 31, 2022 10-K/A 2023-04-28
Q3 2022 -$133M -$31.4M -$1.26M -4.19% Jul 1, 2022 Sep 30, 2022 10-Q 2022-11-10
Q2 2022 -$132M -$33.7M -$29.7M -733% Apr 1, 2022 Jun 30, 2022 10-Q 2022-08-04
Q1 2022 -$102M -$37.5M -$10.9M -40.9% Jan 1, 2022 Mar 31, 2022 10-Q 2022-05-05
Q4 2021 -$91.1M -$30.3M -$65.7M -185% Oct 1, 2021 Dec 31, 2021 10-K/A 2023-04-28
Q3 2021 -$25.4M -$30.1M -$5.04M -20.1% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-10
Q2 2021 -$20.3M -$4.05M +$24.2M +85.7% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-04
Q1 2021 -$44.5M -$26.6M +$602K +2.21% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-05
Q4 2020 -$45.1M $35.4M +$59M Oct 1, 2020 Dec 31, 2020 10-K 2022-03-02
Q3 2020 -$104M -$25.1M -$123M -126% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-04
Q2 2020 $18.9M -$28.2M -$20.2M -253% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-05
Q1 2020 $39.1M -$27.2M -$13.7M -102% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-04
Q4 2019 $52.8M -$23.5M -$20.4M -648% Oct 1, 2019 Dec 31, 2019 10-K 2021-02-25
Q3 2019 $73.2M $97.8M +$107M Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-06
Q2 2019 -$33.4M -$8.01M -$2.37M -42% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-07
Q1 2019 -$31M -$13.5M +$278K +2.02% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-06
Q4 2018 -$31.3M -$3.15M +$8.41M +72.8% Oct 1, 2018 Dec 31, 2018 10-K 2020-02-27
Q3 2018 -$39.7M -$8.74M -$4.35M -99.2% Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-07
Q2 2018 -$35.3M -$5.64M -$2.61M -86.3% Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-07
Q1 2018 -$32.7M -$13.8M -$13.5M -5474% Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-08
Q4 2017 -$19.2M -$11.6M -$16.5M -332% Oct 1, 2017 Dec 31, 2017 10-K 2018-03-08
Q3 2017 -$2.68M -$4.39M -$8.2M -215% Jul 1, 2017 Sep 30, 2017 10-Q 2018-11-13
Q2 2017 $5.52M -$3.03M +$9.33M +75.5% Apr 1, 2017 Jun 30, 2017 10-Q 2018-08-09
Q1 2017 -$3.81M -$247K +$10.7M +97.7% Jan 1, 2017 Mar 31, 2017 10-Q 2018-05-09
Q4 2016 -$14.5M $4.98M Oct 1, 2016 Dec 31, 2016 10-K 2018-03-08
Q3 2016 $3.82M Jul 1, 2016 Sep 30, 2016 10-K 2018-03-08
Q2 2016 -$12.4M Apr 1, 2016 Jun 30, 2016 10-K 2018-03-08
Q1 2016 -$10.9M Jan 1, 2016 Mar 31, 2016 10-K 2018-03-08
* An asterisk sign (*) next to the value indicates that the value is likely invalid.